TUCC physicians remain at the forefront of urologic research through publications and national presentations. We strive to deliver cutting-edge urologic care to our patients and physician participation in clinical research studies is just one way we are able to accomplish our goal.
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
TUCC physician, Lawrence Karsh, M.D., was a lead principal investigator in this Phase III clinical trial, published in The Lancet in February 2011.
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
TUCC physician Lawrence Karsh, M.D., was a lead principal investigator in this Phase III, double-blind, randomised, placebo-controlled study of men with non-metastatic castration-resistant prostate cancer at high risk of bone metastasis published in The Lancet in January 2012.
Clinical evaluation of treatment of Peyronie’s disease with Collagenase Clostridium Histolyticum: Analysis of penile curvature deformity by duration of disease and plaque calcification
TUCC physicians Lawrence Karsh, M.D., and Jesse Mills, M.D., served as lead investigators in three Phase III clinical trials examining the safety and efficacy of collagenase clostridium histolyticum (CCH) in subjects with Peyronie’s disease (PD). The results of this evaluation were presented at the 2013 American Urological Association conference.